Back to search
FDAFDA · Food and drugs·Recall number D-1847-2019

Lamivudine Tablets, USP, 150 mg, 30 (3x10) count Unit Dose Blisters Carton, NDC 60687-362-21 (Individual Dose NDC: 60687-362-11), Distributed by American Health Packaging, Columbus, OH

Published September 18, 2019 · Recall initiated: August 27, 2019

Summary

FDA records drug Class III recall D-1847-2019, published September 18, 2019 and initiated August 27, 2019. Recalling firm: American Health Packaging; Status: Terminated; Reported quantity: 60 cartons; Lot: Lots 186509 and 186982, exp 6/30/2021. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for the tablets.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
American Health Packaging
Distributor
Nationwide
Lot
Lots 186509 and 186982, exp 6/30/2021
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lamivudine Tablets, USP, 150 mg, 30 (3x10) count Unit Dose Blisters Carton, NDC 60687-362-21 (Individual Dose NDC: 60687-362-11), Distributed by American Health Packaging, Columbus, OH recalled?

Yes. FDA published recall D-1847-2019 on September 18, 2019. Reported hazard: Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for the tablets.

What should I do if I have this product?

Voluntary: Firm initiated · Letter